EV
EVARF.US Lombard Medical Inc
- Market cap
- USD 2.80K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2017.
Is EVARF.US undervalued?
Graham numberThe Graham number of Lombard Medical Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lombard Medical Inc fundamental analysis
No fundamental analysis for Lombard Medical Inc yet.
Lombard Medical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lombard Medical Inc
Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. Its principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. The company's products also include Altura endovascular sten…
Full company profileLombard Medical Inc financial statements
2017 annualized: Fiscal year 2017 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2017, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lombard Medical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 6.18M | 6.96M | 13.3M | 15.1M | 12.2M | 9.00M |
| Gross Profit | 2.53M | 2.65M | 5.74M | 6.56M | 955K | - |
| Operating Income | - | -20.0M | -34.6M | -39.5M | -29.3M | - |
| EBITDA | - | - | - | -37.4M | -28.1M | - |
| Net Income | - | -19.2M | -34.8M | -37.8M | -31.0M | - |
| EPS | - | - | - | -2.13 | -1.54 | - |
| Balance Sheet | ||||||
| Total Assets | 15.0M | 58.5M | 72.9M | 85.7M | 67.8M | - |
| Total Liabilities | 8.24M | 9.14M | 8.07M | 42.6M | 53.8M | - |
| Shareholders' Equity | 6.73M | 49.3M | 64.8M | 43.1M | 14.0M | - |
| Cash & Short-term Investments | 4.45M | 40.9M | 53.3M | 32.3M | 20.8M | 8.00M |
| Total Debt | - | - | - | 23.1M | 32.3M | - |
| Cash Flow | ||||||
| Operating Cash Flow | - | -17.8M | -34.4M | -34.4M | -26.6M | - |
| Capital Expenditure | 218K | 1.81M | 1.48M | 1.25M | 265K | - |
| Free Cash Flow | - | - | - | -35.7M | -26.9M | - |
| Ratios | ||||||
| ROE | - | -38.9% | -53.6% | -87.7% | -222.1% | - |
| ROA | - | -32.8% | -47.7% | -44.1% | -45.8% | - |
| Net Profit Margin | - | -275.9% | -261.7% | -250.1% | -255.0% | - |
| Debt to Equity | - | - | - | 0.54x | 2.31x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lombard Medical Inc dividends
Lombard Medical Inc has not paid dividends in the last 5 fiscal years.
Last stock split: 1:200 on Mar 28, 2012.
Who owns Lombard Medical Inc
Ownership data of Lombard Medical Inc is not available yet.
Lombard Medical Inc company profile
- Company name
- Lombard Medical Inc
- Ticker
- EVARF.US
- ISIN
- KYG555981094
- Exchange
- USA Stocks
- Listed since
- Dec 13, 2005
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 113
- Fiscal year end
- December
- Address
- 4 Trident Park, Didcot, United Kingdom, OX11 7HJ
- Phone
- 44 12 3575 0800
- Website
- lombardmedical.com
About Lombard Medical Inc
Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. Its principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. The company's products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement. It sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals. The company was founded in 1994 and is headquartered in Didcot, the United Kingdom.
Lombard Medical Inc management
6- Mr. Kurt B. LemvighChief Executive Officer · born 1960
- Dr. Peter PhillipsChief Technology Officer · born 1959
- Andrew DebbageVice President of Operations
- Mr. Jonathan HornsbyVice President of Sales & Marketing
- Ms. Kate ForsterVice President of Human Resources
- Paul HardwickVice President of Sales